In the approximately 50% of tumours that have a wild-type TP53 gene upon diagnosis, other aberrations in the regulatory networks which control p53 activation are often observed [2–4] including amplification of the MDM2 oncogene. This evidence concerns the gene MDM2 and neoplasm.